| Company Name: |
TargetMol Chemicals Inc.
|
| Tel: |
15002134094 |
| Email: |
marketing@targetmol.cn |
| Products Intro: |
Product Name:Y08284
CAS:2688745-47-1
Package:1removed
|
1-Indolizinecarboxamide, 3-acetyl-N-[3-(1-cyclopropyl-1H-pyrazol-4-yl)-2-fluoro-5-(1-hydroxyethyl)phenyl]-7-methoxy- manufacturers
- Y08284
-
- $1980.00
-
2026-05-11
- CAS:2688745-47-1
- Purity:
- Supply Ability: 10g
|
| | 1-Indolizinecarboxamide, 3-acetyl-N-[3-(1-cyclopropyl-1H-pyrazol-4-yl)-2-fluoro-5-(1-hydroxyethyl)phenyl]-7-methoxy- Basic information |
| | 1-Indolizinecarboxamide, 3-acetyl-N-[3-(1-cyclopropyl-1H-pyrazol-4-yl)-2-fluoro-5-(1-hydroxyethyl)phenyl]-7-methoxy- Chemical Properties |
| density | 1.41±0.1 g/cm3(Predicted) | | pka | 11.84±0.70(Predicted) |
| | 1-Indolizinecarboxamide, 3-acetyl-N-[3-(1-cyclopropyl-1H-pyrazol-4-yl)-2-fluoro-5-(1-hydroxyethyl)phenyl]-7-methoxy- Usage And Synthesis |
| Description | Y08284 is a CBP Bromodomain inhibitor for the treatment of prostate cancer. | | Uses | Y08284 is a potent, selective, oral active CBP bromodomain inhibitor with an IC50 of 4.21 nM. Y08284 suppresses the proliferation of prostate cancer cell lines LNCaP, C4-2B, and 22Rv1. Antitumor activity[1]. | | in vivo | Y08284 demonstrates favorable cell permeability and good pharmacokinetic properties, with oral bioavailability of 25.9%[1]. | | References | [1] Xiang Q, et al. Design, Synthesis, and Biological Evaluation of 1-(Indolizin-3-yl)ethan-1-ones as CBP Bromodomain Inhibitors for the Treatment of Prostate Cancer. J Med Chem. 2022;65(1):785-810. DOI:10.1021/acs.jmedchem.1c01864 |
| | 1-Indolizinecarboxamide, 3-acetyl-N-[3-(1-cyclopropyl-1H-pyrazol-4-yl)-2-fluoro-5-(1-hydroxyethyl)phenyl]-7-methoxy- Preparation Products And Raw materials |
|